Moclobemide in elderly patients with cognitive decline and depression. An international double-blind, placebo-controlled trial.
Examined the effects of the monoamine oxidase inhibitor (MAOI) moclobemide on dementia and depression in a double-blind placebo-controlled study with 694 elderly patients (aged 60-90 years). Patients met Diagnostic and Statistical Manual of Mental Disorders-III-Revised (DSM-III) criteria for dementia and suffered from accompanying depression or met DSM-III criteria for major depressive episode and suffered from accompanying cognitive decline. Changes were assessed with the Hamilton Rating Scale for Depression (HAM-D), Mini-Mental State Examination (MMSE), Sandoz Clinical Assessment Geriatric Scale (SCAG), Geriatric Depression Scale (GDS), Clinical Global Assessment of Efficacy (CGAE), and the Rating Scale for Geriatric Patients (BGP). Results showed that moclobemide significantly improved depressive symptoms without producing any decline in cognitive function or side effects greater than in the placebo group.
Dieser Eintrag ist freigegeben.